News from actavis, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 26, 2015, 17:30 ET

Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC

 Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Securities and Exchange Commission has declared effective...

Jan 26, 2015, 07:30 ET

Actavis to Acquire Auden Mckenzie for 306M GBP

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and the owners of Auden Mckenzie Holdings Limited, a dynamic and...

Jan 20, 2015, 02:00 ET

Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

 Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced positive results from a Phase III trial evaluating the efficacy and safety of...

Jan 13, 2015, 08:00 ET

Actavis Launches U.S. Generic Specialty Injectable Portfolio

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the launch of a leading portfolio of generic...

Jan 12, 2015, 08:30 ET

Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance

 Actavis plc (NYSE: ACT), in advance of the start of  the 33rd Annual J.P. Morgan Healthcare Conference, today announced that based on a...

Jan 12, 2015, 08:00 ET

Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings

 Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Federal Trade Commission (FTC) has granted early...

Jan 06, 2015, 15:54 ET

Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR

 Actavis plc (NYSE: ACT) today confirmed that the U.S. Court of Appeals for the Second Circuit granted the Company's motion to expedite its...

Jan 06, 2015, 02:00 ET

Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of...

Dec 24, 2014, 13:15 ET

Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension

 Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration...

Dec 24, 2014, 08:00 ET

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

 Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has...

Dec 22, 2014, 09:24 ET

Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Jonathon Kellerman has joined the Company as...

Dec 22, 2014, 09:00 ET

Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...

Dec 19, 2014, 16:15 ET

XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults

 Actavis plc (NYSE: ACT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Dec 19, 2014, 09:00 ET

Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

 Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis,...

Dec 16, 2014, 07:30 ET

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition

 Actavis plc (NYSE: ACT) today announced the planned senior management team that will lead the global pharmaceutical company following the...

Dec 15, 2014, 15:11 ET

Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR

 Actavis plc (NYSE: ACT) today confirmed that it is filing an emergency appeal to the U.S. Court of Appeals for the Second Circuit seeking to...

Dec 11, 2014, 18:52 ET

Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR

 Actavis plc (NYSE: ACT) today confirmed that Judge Robert Sweet of the United States District Court for the Southern District of New...

Dec 10, 2014, 09:28 ET

Actavis Launches Generic Version of Celebrex®

Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Celebrex®  (celecoxib) 50 mg, 100 mg, 200 mg and...

Dec 05, 2014, 16:46 ET

Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam

 Actavis plc (NYSE: ACT) today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration...

Dec 01, 2014, 16:05 ET

Actavis Launches Generic Version of Intuniv®

 Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Intuniv® (guanfacine...